Table 2.
Effect of chronic resveratrol (resv) treatment on the metabolic profiles of NASH mice
| Ctrl (n=5) | NASH (n=9) | NASH-resv (n=9) | NASH-resv-EX527 (n=9) | |
| (Triglyceride, TG, mg/dL) | 55±4.8 | 209±28* | 124±17† | 167±9 |
| (Fasting glucose) (mg/dL) | 99±8 | 189±21* | 118±16† | 158±13 |
| (Fasting insulin) (ng/mL) | 1.4±0.09 | 5.8±0.68* | 3.4±0.78† | 4.7±0.42 |
| HOMA-IR index | 2.4±0.1 | 18.8±2.1* | 6.9±1.3† | 12.8±0.8 |
| (Aspartate aminotransferase) (AST, U/L) | 52.3±4.9 | 145.7±5.2* | 98.5±11.4† | 114.8±10.3 |
| (Alanine aminotransferase) (ALT, U/L) | 49.1±7.1 | 120.3±20.1* | 84.4±9.6†† | 114.5±1.6 |
| Hepatic hydroxyproline content (μg/mg liver weight) | 0.19±0.02 | 0.79±0.07* | 0.35±0.02† | 0.64±0.03 |
Ctrl/NASH/NASH-resv: mice receiving 12 week of high-fat diet (HFD)+MCD diet or normal chow (NC) feeding and vehicle or resv (resveratrol, 30 mg/kg/day) treatment for 6 week from the 7th to 12th weeks of HFD+MCD feeding; NASH-resv+EX527: NASH mice are concomitant receiving resveratrol and EX-527 (SIRT1 inhibitor) treatment. HOMA-IR: homeostasis model assessment-insulin-resistance, calculated as ((fasting glucose)×(fasting insulin))/58.32.
*p<0.05 vs Ctrl group.
†p<0.05 vs NASH group.
HOMA-IR, homeostasis model assessment-insulin-resistance; MCD, methionine and choline deficient; NASH, non-alcoholic steatohepatitis.